← FDA Drug Approvals (Drugs@FDA)

DIFLUPREDNATE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: ALEMBIC · Approved 2026-01-26

Drug application

FDA Application #

ANDA213774

Application type

Abbreviated New Drug Application (Generic)

Brand name

DIFLUPREDNATE

Generic name

DIFLUPREDNATE OPHTHALMIC

Active ingredients

DIFLUPREDNATE

Dosage form

EMULSION

Route

OPHTHALMIC

Marketing status

Prescription

Sponsor

ALEMBIC

Manufacturer

Alembic Pharmaceuticals Inc.

First approval

2026-01-26

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown